159 related articles for article (PubMed ID: 36074674)
21. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index.
Kapucuoglu N; Aktepe F; Kaya H; Bircan S; Karahan N; Ciriş M
Pathol Res Pract; 2007; 203(3):153-62. PubMed ID: 17317031
[TBL] [Abstract][Full Text] [Related]
23. Intratumoral effects of medroxy-progesterone on proliferation, apoptosis, and sex steroid receptors in endometrioid endometrial adenocarcinoma.
Dahmoun M; Boman K; Cajander S; Bäckström T
Gynecol Oncol; 2004 Jan; 92(1):116-26. PubMed ID: 14751147
[TBL] [Abstract][Full Text] [Related]
24. Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors.
Bartosch C; Monteiro-Reis S; Vieira R; Pereira A; Rodrigues M; Jerónimo C; Lopes JM
PLoS One; 2015; 10(8):e0134969. PubMed ID: 26252518
[TBL] [Abstract][Full Text] [Related]
25. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
26. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.
Rahman MT; Nakayama K; Ishikawa M; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Iida K; Miyazaki K
Oncology; 2013; 84(3):166-73. PubMed ID: 23306391
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H
Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591
[TBL] [Abstract][Full Text] [Related]
28. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future anti-androgen therapy in endometrial cancers.
Moatamed NA; Vahdatshariatpanahi S; Gjertson DW; Sachs CR; Kang Y; Ostrzega N; Huang J; Memarzadeh S
PLoS One; 2023; 18(9):e0291361. PubMed ID: 37725629
[TBL] [Abstract][Full Text] [Related]
30. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.
Halperin R; Zehavi S; Habler L; Hadas E; Bukovsky I; Schneider D
Eur J Gynaecol Oncol; 2001; 22(2):122-6. PubMed ID: 11446475
[TBL] [Abstract][Full Text] [Related]
31. [Immunohistochemical profile of endometrioid adenocarcinoma of the uterus: ER, PR, HER-2, Ki-67 and their prognostic value].
Pozharisskiĭ KM; Samsonova EA; Ten VP; Maksimova NA; Urmancheeva AF
Arkh Patol; 2005; 67(2):13-7. PubMed ID: 15938112
[TBL] [Abstract][Full Text] [Related]
32. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
[TBL] [Abstract][Full Text] [Related]
33. Apoptosis, proliferation, and hormone receptors in endometrial carcinoma: results depending on methods of analysis.
Dahmoun M; Bäckström T; Boman K; Cajander S
Int J Oncol; 2003 Jan; 22(1):115-22. PubMed ID: 12469193
[TBL] [Abstract][Full Text] [Related]
34. Androgen Receptor Expression in Endometrial Carcinoma.
Zadeh SL; Duska LR; Mills AM
Int J Gynecol Pathol; 2018 Mar; 37(2):167-173. PubMed ID: 28582344
[TBL] [Abstract][Full Text] [Related]
35. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
[TBL] [Abstract][Full Text] [Related]
36. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
[TBL] [Abstract][Full Text] [Related]
37. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma.
Li SF; Shiozawa T; Nakayama K; Nikaido T; Fujii S
Cancer; 1996 Jan; 77(2):321-9. PubMed ID: 8625241
[TBL] [Abstract][Full Text] [Related]
38. p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy.
Bonfitto VL; de Angelo Andrade LA
Sao Paulo Med J; 2003 Jul; 121(4):163-6. PubMed ID: 14595509
[TBL] [Abstract][Full Text] [Related]
39. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.
Köbel M; Atenafu EG; Rambau PF; Ferguson SE; Nelson GS; Ho TC; Panzarella T; McAlpine JN; Gilks CB; Clarke BA; Bernardini MQ
Gynecol Oncol; 2016 Jun; 141(3):559-563. PubMed ID: 27072807
[TBL] [Abstract][Full Text] [Related]
40. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
Alkushi A; Köbel M; Kalloger SE; Gilks CB
Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
